DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $77,974,134 | +44.4% | 314,285 | +39.7% | 2.04% | +20.4% |
| Q2 2023 | $54,011,447 | -16.3% | 225,048 | -12.1% | 1.70% | -21.1% |
| Q1 2023 | $64,551,274 | +53.3% | 256,115 | +61.4% | 2.15% | +50.0% |
| Q4 2022 | $42,108,935 | +1.0% | 158,650 | -1.8% | 1.43% | -3.1% |
| Q3 2022 | $41,708,000 | +1.4% | 161,477 | -0.5% | 1.48% | +6.9% |
| Q2 2022 | $41,128,000 | -13.5% | 162,226 | +0.1% | 1.38% | +3.7% |
| Q1 2022 | $47,559,000 | -12.7% | 162,133 | -2.1% | 1.33% | -5.7% |
| Q4 2021 | $54,480,000 | +8.9% | 165,586 | +0.7% | 1.41% | -0.3% |
| Q3 2021 | $50,041,000 | +7.4% | 164,372 | -5.3% | 1.42% | +5.2% |
| Q2 2021 | $46,596,000 | +18.2% | 173,634 | -0.9% | 1.35% | +8.7% |
| Q1 2021 | $39,438,000 | +1.6% | 175,216 | +0.3% | 1.24% | -3.0% |
| Q4 2020 | $38,816,000 | -0.3% | 174,736 | -3.3% | 1.28% | -12.5% |
| Q3 2020 | $38,927,000 | +20.3% | 180,778 | -1.2% | 1.46% | +12.9% |
| Q2 2020 | $32,355,000 | +29.8% | 182,974 | +1.6% | 1.30% | +4.8% |
| Q1 2020 | $24,924,000 | -10.4% | 180,074 | -0.7% | 1.24% | +12.2% |
| Q4 2019 | $27,819,000 | +6.4% | 181,255 | +0.1% | 1.10% | -4.2% |
| Q3 2019 | $26,144,000 | +2.0% | 181,018 | +0.9% | 1.15% | -0.9% |
| Q2 2019 | $25,639,000 | +2977.9% | 179,397 | +2744.4% | 1.16% | +1835.0% |
| Q1 2019 | $833,000 | +22.5% | 6,307 | -4.3% | 0.06% | +11.1% |
| Q4 2018 | $680,000 | -7.9% | 6,590 | -3.0% | 0.05% | +3.8% |
| Q3 2018 | $738,000 | +8.7% | 6,796 | 0.0% | 0.05% | +6.1% |
| Q2 2018 | $679,000 | -1.9% | 6,796 | -3.8% | 0.05% | -9.3% |
| Q1 2018 | $692,000 | -8.2% | 7,068 | -13.0% | 0.05% | -10.0% |
| Q4 2017 | $754,000 | +8.5% | 8,127 | +0.3% | 0.06% | 0.0% |
| Q3 2017 | $695,000 | -3.1% | 8,104 | -8.0% | 0.06% | -1.6% |
| Q2 2017 | $717,000 | -8.0% | 8,804 | -6.2% | 0.06% | -11.6% |
| Q1 2017 | $779,000 | +23.1% | 9,389 | +15.5% | 0.07% | +13.1% |
| Q4 2016 | $633,000 | +4.5% | 8,129 | +5.2% | 0.06% | -15.3% |
| Q3 2016 | $606,000 | -14.6% | 7,729 | +10.0% | 0.07% | -18.2% |
| Q2 2016 | $710,000 | +6.4% | 7,029 | 0.0% | 0.09% | +11.4% |
| Q1 2016 | $667,000 | -10.6% | 7,029 | -12.5% | 0.08% | -12.2% |
| Q4 2015 | $746,000 | +52.6% | 8,029 | +39.9% | 0.09% | +40.6% |
| Q3 2015 | $489,000 | -3.7% | 5,740 | -3.4% | 0.06% | -5.9% |
| Q2 2015 | $508,000 | +0.8% | 5,940 | 0.0% | 0.07% | -5.6% |
| Q1 2015 | $504,000 | -6.1% | 5,940 | -5.2% | 0.07% | -11.1% |
| Q4 2014 | $537,000 | +12.8% | 6,263 | 0.0% | 0.08% | +8.0% |
| Q3 2014 | $476,000 | 0.0% | 6,263 | +3.7% | 0.08% | -1.3% |
| Q2 2014 | $476,000 | +10.7% | 6,040 | +5.2% | 0.08% | +8.6% |
| Q1 2014 | $430,000 | -4.0% | 5,740 | -1.1% | 0.07% | -2.8% |
| Q4 2013 | $448,000 | +10.6% | 5,803 | -0.8% | 0.07% | +1.4% |
| Q3 2013 | $405,000 | +7.4% | 5,848 | -1.7% | 0.07% | +1.4% |
| Q2 2013 | $377,000 | – | 5,951 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |